| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2022 | FANNIN PARTNERS LLC | 3900 ESSEX LN | HOUSTON | TX | 77027-5175 | HARRIS | USA | R44OD030205 | Aptamer therapeutic for safe and low-cost treatment of snake bite envenomation | 000 | 2 | NIH | 11/13/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $320,000 ) |
| | 2024 | 2024 | FANNIN PARTNERS LLC | 3900 ESSEX LN | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43DA060646 | Investigation of a Novel PDE4B Inhibitor for Stimulant Use Disorder | 000 | 1 | NIH | 4/19/2024 | $320,000 |
| | 2024 | 2020 | FANNIN PARTNERS LLC | 3900 ESSEX LN | HOUSTON | TX | 77027-5175 | HARRIS | USA | R44HD094456 | Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery | 000 | 3 | NIH | 2/14/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $284,287 ) |
| | 2023 | 2023 | FANNIN PARTNERS LLC | 3900 ESSEX LN | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43FD007809 | Bedside right-heart catheterization for early diagnosis and more effective management of patients with heart failure and primary pulmonary hypertension | 000 | 1 | FDA | 9/29/2023 | $199,972 |
| | 2023 | 2023 | FANNIN PARTNERS LLC | 3900 ESSEX LN | HOUSTON | TX | 77027-5175 | HARRIS | USA | R44CA268530 | Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia | 001 | 1 | NIH | 9/14/2023 | $84,315 |
| | 2023 | 2022 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R44CA268530 | Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia | 000 | 1 | NIH | 3/16/2023 | $0 |
| | 2023 | 2020 | FANNIN PARTNERS LLC | 3900 ESSEX LN | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43DA053124 | Novel inhibitor of PDE4 for the treatment of opioid use disorder | 000 | 1 | NIH | 9/8/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $2,278,261 ) |
| | 2022 | 2022 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R44OD030205 | Aptamer therapeutic for safe and low-cost treatment of snake bite envenomation | 000 | 2 | NIH | 6/29/2022 | $978,343 |
| | 2022 | 2022 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43GM143972 | Expediting the Biomarker Discovery Process Through a Novel Bead-Based Aptamer Capture Platform | 000 | 1 | NIH | 8/15/2022 | $299,921 |
| | 2022 | 2022 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R44CA268530 | Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia | 000 | 1 | NIH | 3/30/2022 | $999,997 |
| | 2022 | 2021 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R44HD094456 | Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery | 001 | 3 | NIH | 6/29/2022 | $0 |
| | 2022 | 2020 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43DA053124 | Novel inhibitor of PDE4 for the treatment of opioid use disorder | 000 | 1 | NIH | 3/2/2022 | $0 |
| | 2022 | 2020 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R44HD094456 | Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery | 000 | 3 | NIH | 6/29/2022 | $0 |
| | 2022 | 2019 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43DK123908 | Artificial Urethral Sphincter for Control of Urinary Incontinence in Pediatric Patients | 001 | 1 | NIH | 2/16/2022 | $0 |
| | 2022 | 2019 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43DK123908 | Artificial Urethral Sphincter for Control of Urinary Incontinence in Pediatric Patients | 000 | 1 | NIH | 12/27/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,133,701 ) |
| | 2021 | 2021 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R44OD030205 | Aptamer therapeutic for safe and low-cost treatment of snake bite envenomation | 001 | 1 | NIH | 7/31/2021 | $0 |
| | 2021 | 2021 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R44HD094456 | Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery | 002 | 3 | NIH | 5/19/2021 | $0 |
| | 2021 | 2021 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R44HD094456 | Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery | 000 | 3 | NIH | 2/28/2021 | $139,727 |
| | 2021 | 2021 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R44OD030205 | Aptamer therapeutic for safe and low-cost treatment of snake bite envenomation | 000 | 1 | NIH | 6/23/2021 | $993,974 |
| | 2021 | 2020 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R44HD094456 | Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery | 001 | 3 | NIH | 5/19/2021 | $0 |
| | 2021 | 2020 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43DA053124 | Novel inhibitor of PDE4 for the treatment of opioid use disorder | 000 | 1 | NIH | 10/22/2020 | $0 |
| | 2021 | 2020 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43DA053124 | Novel inhibitor of PDE4 for the treatment of opioid use disorder | 001 | 1 | NIH | 7/14/2021 | $0 |
| | 2021 | 2018 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43AG062064 | Innovative Delivery of siRNA across the Blood Brain Barrier | 000 | 1 | NIH | 3/12/2021 | $0 |
| | 2021 | 2018 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R44AI125007 | Preclinical evaluation of a novel small molecule STAT inhibitor | 000 | 3 | NIH | 2/6/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,331,372 ) |
| | 2020 | 2020 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R44HD094456 | Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery | 000 | 3 | NIH | 7/2/2020 | $981,505 |
| | 2020 | 2020 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43DA053124 | Novel inhibitor of PDE4 for the treatment of opioid use disorder | 000 | 1 | NIH | 9/16/2020 | $349,867 |
| | 2020 | 2019 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43DK123908 | Artificial Urethral Sphincter for Control of Urinary Incontinence in Pediatric Patients | 001 | 1 | NIH | 12/16/2019 | $0 |
| | 2020 | 2019 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43DK123908 | Artificial Urethral Sphincter for Control of Urinary Incontinence in Pediatric Patients | 000 | 1 | NIH | 11/26/2019 | $0 |
| | 2020 | 2018 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R44AI125007 | Preclinical evaluation of a novel small molecule STAT inhibitor | 000 | 3 | NIH | 3/18/2020 | $0 |
| | 2020 | 2017 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43DK115336 | Ureteral Stent Electromagnetic Removal (USER) Device for Pediatric Patients | 000 | 1 | NIH | 12/19/2019 | $0 |
| | 2020 | 2017 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43TR002043 | Reconstituted High Density Lipoprotein Particles as siRNA Carriers | 000 | 1 | NIH | 8/6/2020 | $0 |
| | 2020 | 2017 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43AI131867 | Novel Small Molecule Targeting STAT Proteins for the Management of Atopic Dermatitis | 000 | 1 | NIH | 12/27/2019 | $0 |
| | 2020 | 2017 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43HD094456 | Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery | 000 | 1 | NIH | 12/19/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $2,278,414 ) |
| | 2019 | 2019 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43DK123908 | Artificial Urethral Sphincter for Control of Urinary Incontinence in Pediatric Patients | 000 | 1 | NIH | 9/13/2019 | $224,771 |
| | 2019 | 2019 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43TR002043 | Reconstituted High Density Lipoprotein Particles as siRNA Carriers | 000 | 1 | NIH | 2/5/2019 | $55,000 |
| | 2019 | 2019 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R44HD094456 | Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery | 000 | 2 | NIH | 7/22/2019 | $998,650 |
| | 2019 | 2018 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43AG062064 | Innovative Delivery of siRNA across the Blood Brain Barrier | 000 | 1 | NIH | 7/30/2019 | $0 |
| | 2019 | 2018 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R44AI125007 | Preclinical evaluation of a novel small molecule STAT inhibitor | 001 | 3 | NIH | 12/24/2018 | $999,993 |
| | 2019 | 2017 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43HD094456 | Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery | 000 | 1 | NIH | 7/19/2019 | $0 |
| | 2019 | 2017 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43DK115336 | Ureteral Stent Electromagnetic Removal (USER) Device for Pediatric Patients | 000 | 1 | NIH | 11/12/2018 | $0 |
| | 2019 | 2017 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43TR002043 | Reconstituted High Density Lipoprotein Particles as siRNA Carriers | 001 | 1 | NIH | 6/25/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $224,989 ) |
| | 2018 | 2018 | FANNIN PARTNERS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R43AG062064 | Innovative Delivery of siRNA across the Blood Brain Barrier | 000 | 1 | NIH | 9/21/2018 | $224,989 |
|
|
